Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 37NAD+ (Nicotinamide Adenine Dinucleotide) literatureeuropepmc · Preclinical2026

Engineering of fructose-6-phosphate aldolase for one-carbon conversion to mannitol in a designed biotransformation system.

The engineered FSA variants showed a 34-fold increase in efficiency and achieved an 88% yield in converting methanol to mannitol, but these findings are limited to in vitro conditions.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
17
Preclinical · this one
15
Observational
0
Open-label
1
Randomised
4
Reviews

Summary and findings

This study investigates the engineering of fructose-6-phosphate aldolase (FSA) to enhance its catalytic efficiency for converting methanol to mannitol. The engineered variants exhibited a 34-fold increase in catalytic efficiency compared to the wildtype, achieving a yield of 88% in an in vitro cascade. No therapeutic claims are made.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
34-fold increase in catalytic efficiency compared to wildtype FSA.Preclinical2026

Abstract

The authors’ words, as europepmc supplied them

Developing artificial synthetic pathways for converting one-carbon compounds into value-added chemicals represents a promising strategy for carbon-neutral manufacturing. Enzymatic C-C bond formation plays a central role in carbon-chain extension and structural diversification. Fructose-6-phosphate aldolase (FSA) has been employed in <i>in vitro</i> multienzyme systems for producing starch and sugars from methanol. However, its atomistic catalytic mechanism has remained unclear, limiting rational enzyme engineering. Here, we elucidate the aldol reaction mechanism between dihydroxyacetone (DHA) and glyceraldehyde-3-phosphate (GALP) catalyzed by FSA using QM/MM calculations, identifying the Schiff-base/iminium formation step as the rate-limiting step in the aldol condensation. Guided by this mechanism, we engineered FSA variants with a 34-fold increase in catalytic efficiency compared with the wildtype. We further integrated the engineered FSA into a designed <i>in vitro</i> cascade converting methanol to mannitol, achieving a high yield of 88%. Collectively, these mechanistic insights and improved biocatalysts expand the toolkit for green enzymatic C-C bond formation and one-carbon utilization.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

CThe mitochondrial deacetylase SIRT3 is nonessential for cyclophilin D-dependent procoagulant platelet formation in mice.Platelets · 2026 · Not reported in abstract.AnimalDA comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.Journal of enzyme inhibition and medicinal chemistry · 2026 · 31 of 46 FDA-approved drugs in 2025 were small molecule drugs.reviewCNicotinamide-derived tumor-targeting carbon dots for Cancer Photothermal therapy.Journal of colloid and interface science · 2026 · Binding energy of NAM-CDs to Ki67 was -7.7 kcal/mol.AnimalCMitochondrial-targeted nano-enhancer driving a self-amplifying NAD&lt;sup&gt;+&lt;/sup&gt; feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration.Biomaterials · 2026In vitroDPyridoxal photoenzymes for asymmetric radical-radical cross-couplings.Nature · 2026CPhage anti-defense genes targeting NAD&lt;sup&gt;+&lt;/sup&gt; metabolism and DNA replication are associated with a broad host range against &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt;.Virulence · 2026 · Not reported in abstract.Animal